{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:05:30Z","timestamp":1793318730523,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03132-z","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T02:21:47Z","timestamp":1751941307000},"page":"23-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Venous thromboembolism prevention and treatment with factor XI\/XIa inhibitors: current status and future perspectives"],"prefix":"10.1007","volume":"59","author":[{"given":"Raul","family":"Del Toro-Mijares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo","family":"Porres-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso J.","family":"Tafur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilham","family":"Benzidia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Cueto-Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D","family":"Douketis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"1","key":"3132_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pharmthera.2010.12.007","volume":"130","author":"T Mavrakanas","year":"2011","unstructured":"Mavrakanas T, Bounameaux H (2011) The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther 130(1):46\u201358. https:\/\/doi.org\/10.1016\/j.pharmthera.2010.12.007","journal-title":"Pharmacol Ther"},{"issue":"14","key":"3132_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"The EINSTEIN","year":"2012","unstructured":"The EINSTEIN\u2013PE Investigators (2012) Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297. https:\/\/doi.org\/10.1056\/NEJMoa1113572","journal-title":"N Engl J Med"},{"issue":"9","key":"3132_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U et al (2013) Oral Apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507","journal-title":"N Engl J Med"},{"issue":"17","key":"3132_CR4","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM, Cohen A et al (2020) Apixaban for the treatment of venous thromboembolism associated with Cancer. N Engl J Med 382(17):1599\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1915103","journal-title":"N Engl J Med"},{"issue":"24","key":"3132_CR5","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/nejmoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352. https:\/\/doi.org\/10.1056\/nejmoa0906598","journal-title":"N Engl J Med"},{"issue":"15","key":"3132_CR6","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","unstructured":"The Hokusai-VTE Investigators (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406\u20131415. https:\/\/doi.org\/10.1056\/NEJMoa1306638","journal-title":"N Engl J Med"},{"issue":"8","key":"3132_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s11239-024-03062-2","volume":"57","author":"GD Barnes","year":"2024","unstructured":"Barnes GD, Gorog DA (2024) Novel antithrombotic approaches in cardiovascular disease\u2013 what is on the horizon? J Thromb Thrombolysis 57(8):1281\u20131282. https:\/\/doi.org\/10.1007\/s11239-024-03062-2","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"3132_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jaccao.2023.09.003","volume":"5","author":"L Bertoletti","year":"2023","unstructured":"Bertoletti L, Madridano O, Jim\u00e9nez D, Muriel A, Bikdeli B, Ay C, Trujillo-Santos J et al (2023) Cancer-Associated thrombosis. JACC CardioOncol 5(6):758\u2013772. https:\/\/doi.org\/10.1016\/j.jaccao.2023.09.003","journal-title":"JACC CardioOncol"},{"issue":"12","key":"3132_CR9","doi-asserted-by":"publisher","first-page":"e2345883","DOI":"10.1001\/jamanetworkopen.2023.45883","volume":"6","author":"SJ Simon","year":"2023","unstructured":"Simon SJ, Patell R, Zwicker JI, Kazi DS, Hollenbeck BL (2023) Venous thromboembolism in total hip and total knee arthroplasty. JAMA Netw Open 6(12):e2345883. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.45883","journal-title":"JAMA Netw Open"},{"issue":"6","key":"3132_CR10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","volume":"100","author":"J Eikelboom","year":"2021","unstructured":"Eikelboom J, Floege J, Thadhani R, Weitz JI, Winkelmayer WC (2021) Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney Int 100(6):1199\u20131207. https:\/\/doi.org\/10.1016\/j.kint.2021.08.028","journal-title":"Kidney Int"},{"key":"3132_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fmed.2017.00019","volume":"4","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Fredenburgh JC (2017) Factors XI and XII as targets for new anticoagulants. Front Med 4:19. https:\/\/doi.org\/10.3389\/fmed.2017.00019","journal-title":"Front Med"},{"issue":"8","key":"3132_CR12","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s11239-024-02985-0","volume":"57","author":"AE Ali","year":"2024","unstructured":"Ali AE, Becker RC (2024) The foundation for investigating factor XI as a target for Inhibition in human cardiovascular disease. J Thromb Thrombolysis 57(8):1283\u20131296. https:\/\/doi.org\/10.1007\/s11239-024-02985-0","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"3132_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1358863X231206778","volume":"29","author":"S Prakash","year":"2024","unstructured":"Prakash S, Mares AC, Porres-Aguilar M, Mukherjee D, Barnes GD (2024) Factor xi\/xia inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review. Vasc Med 29(1):85\u201392. https:\/\/doi.org\/10.1177\/1358863X231206778","journal-title":"Vasc Med"},{"issue":"3","key":"3132_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ehjcvp\/pvae002","volume":"10","author":"G Occhipinti","year":"2024","unstructured":"Occhipinti G, Laudani C, Spagnolo M, Finocchiaro S, Mazzone PM, Faro DC, Mauro MS et al (2024) Pharmacological and clinical appraisal of factor XI inhibitor drugs. Eur Heart J Cardiovasc Pharmacother 10(3):245\u2013258. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae002","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"3132_CR15","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","volume":"111","author":"O Salomon","year":"2008","unstructured":"Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U (2008) Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 111(8):4113\u20134117. https:\/\/doi.org\/10.1182\/blood-2007-10-120139","journal-title":"Blood"},{"issue":"9","key":"3132_CR16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, Rennert G, Saliba W (2017) Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 129(9):1210\u20131215. https:\/\/doi.org\/10.1182\/blood-2016-09-742262","journal-title":"Blood"},{"issue":"10333","key":"3132_CR17","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/s0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA et al (2022) Safety of the oral factor XIa inhibitor asundexian compared with Apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 399(10333):1383\u20131390. https:\/\/doi.org\/10.1016\/s0140-6736(22)00456-1","journal-title":"Lancet"},{"issue":"1","key":"3132_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/nejmoa2407105","volume":"392","author":"JP Piccini","year":"2025","unstructured":"Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, Chang-Sheng M et al (2025) Asundexian versus Apixaban in patients with atrial fibrillation. N Engl J Med 392(1):23\u201332. https:\/\/doi.org\/10.1056\/nejmoa2407105","journal-title":"N Engl J Med"},{"issue":"4","key":"3132_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1056\/NEJMoa2406674","volume":"392","author":"CT Ruff","year":"2025","unstructured":"Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, Goodrich EL et al (2025) Abelacimab versus Rivaroxaban in patients with atrial fibrillation. N Engl J Med 392(4):361\u2013371. https:\/\/doi.org\/10.1056\/NEJMoa2406674","journal-title":"N Engl J Med"},{"issue":"10357","key":"3132_CR20","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/s0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A et al (2022) Factor XIa Inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 400(10357):997\u20131007. https:\/\/doi.org\/10.1016\/s0140-6736(22)01588-4","journal-title":"Lancet"},{"issue":"1","key":"3132_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/s1474-4422(23)00403-9","volume":"23","author":"M Sharma","year":"2024","unstructured":"Sharma M, Molina CA, Toyoda K, Bereczki D, Bangdiwala SI, Kasner SE, Lutsep HL et al (2024) Safety and efficacy of factor XIa Inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 23(1):46\u201359. https:\/\/doi.org\/10.1016\/s1474-4422(23)00403-9","journal-title":"Lancet Neurol"},{"issue":"1","key":"3132_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11239-024-02986-z","volume":"58","author":"AE Ali","year":"2025","unstructured":"Ali AE, Awad MK, Ali K, Abouzid MR, Ahmed MH, Mazroua MS (2025) Factor XI as a new target for prevention of thromboembolism in cardiovascular disease: a meta-analysis of randomized controlled trials. J Thromb Thrombolysis 58(1):1\u201314. https:\/\/doi.org\/10.1007\/s11239-024-02986-z","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"3132_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1053\/j.seminhematol.2007.02.004","volume":"44","author":"M Cushman","year":"2007","unstructured":"Cushman M (2007) Epidemiology and risk factors for venous thrombosis. Seminars Hematol 44(2):62\u201369. https:\/\/doi.org\/10.1053\/j.seminhematol.2007.02.004","journal-title":"Seminars Hematol"},{"key":"3132_CR24","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/j.1538-7836.2005.01415.x","volume":"3","author":"JA Heit","year":"2005","unstructured":"Heit JA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3:1611\u20131617. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01415.x","journal-title":"J Thromb Haemost"},{"issue":"26","key":"3132_CR25","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/nejmoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitzs F et al (2008) Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358(26):2776\u20132786. https:\/\/doi.org\/10.1056\/nejmoa076016","journal-title":"N Engl J Med"},{"issue":"11","key":"3132_CR26","doi-asserted-by":"publisher","first-page":"800","DOI":"10.7326\/0003-4819-158-11-201306040-00004","volume":"158","author":"DR Anderson","year":"2013","unstructured":"Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, Fisher W et al (2013) Aspirin versus Low-Molecular-Weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: A randomized trial. Ann Intern Med 158(11):800\u2013806. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00004","journal-title":"Ann Intern Med"},{"issue":"8","key":"3132_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/nejmoa1712746","volume":"378","author":"DR Anderson","year":"2018","unstructured":"Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, Pelet S et al (2018) Aspirin or Rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med 378(8):699\u2013707. https:\/\/doi.org\/10.1056\/nejmoa1712746","journal-title":"N Engl J Med"},{"issue":"8","key":"3132_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jama.2022.13416","volume":"328","author":"VS Sidhu","year":"2022","unstructured":"Sidhu VS, Kelly T-L, Pratt N, Graves SE, Buchbinder R, Adie S, Cashman K et al (2022) Effect of aspirin vs Enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial. JAMA 328(8):719\u2013727. https:\/\/doi.org\/10.1001\/jama.2022.13416","journal-title":"JAMA"},{"issue":"5","key":"3132_CR29","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/ksa.12456","volume":"33","author":"LA Salman","year":"2024","unstructured":"Salman LA, Altahtamouni SB, Khatkar H, Al-Ani A, Hameed S, Alvand A (2024) The efficacy of aspirin versus low\u2010molecular\u2010weight heparin for venous thromboembolism prophylaxis after knee and hip arthroplasty: A systematic review and meta\u2010analysis of randomized controlled trials. Knee Surg Sports Traumatol Arthrosc 33(5):1605\u20131616. https:\/\/doi.org\/10.1002\/ksa.12456","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"issue":"7","key":"3132_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, B\u00fcller HR, Raskob GE et al (2021) Abelacimab for prevention of venous thromboembolism. N Engl J Med 385(7):609\u2013617. https:\/\/doi.org\/10.1056\/NEJMoa2105872","journal-title":"N Engl J Med"},{"issue":"3","key":"3132_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR B\u00fcller","year":"2015","unstructured":"B\u00fcller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A et al (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372(3):232\u2013240. https:\/\/doi.org\/10.1056\/NEJMoa1405760","journal-title":"N Engl J Med"},{"issue":"23","key":"3132_CR32","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, Mahaffey KW et al (2021) Milvexian for the prevention of venous thromboembolism. N Engl J Med 385(23):2161\u20132172. https:\/\/doi.org\/10.1056\/NEJMoa2113194","journal-title":"N Engl J Med"},{"issue":"2","key":"3132_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C et al (2020) Effect of Osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA 323(2):130\u2013139. https:\/\/doi.org\/10.1001\/jama.2019.20687","journal-title":"JAMA"},{"issue":"1","key":"3132_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F et al (2022) Cancer-associated venous thromboembolism. Nat Rev Dis Primers 8(1):11. https:\/\/doi.org\/10.1038\/s41572-022-00336-y","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"3132_CR35","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/atvbaha.123.318779","volume":"43","author":"L Girardi","year":"2023","unstructured":"Girardi L, Wang T-F, Ageno W, Carrier M (2023) Updates in the incidence, pathogenesis, and management of Cancer and venous thromboembolism. Arterioscler Thromb Vasc Biol 43(6):824\u2013831. https:\/\/doi.org\/10.1161\/atvbaha.123.318779","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"3132_CR36","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","volume":"42","author":"E Grilz","year":"2021","unstructured":"Grilz E, Posch F, Nopp S, K\u00f6nigsbr\u00fcgge O, Lang IM, Klimek P, Thurner S et al (2021) Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer\u2014a nationwide analysis. Eur Heart J 42(23):2299\u20132307. https:\/\/doi.org\/10.1093\/eurheartj\/ehab171","journal-title":"Eur Heart J"},{"issue":"6","key":"3132_CR37","doi-asserted-by":"publisher","first-page":"CD006650","DOI":"10.1002\/14651858.cd006650.pub5","volume":"6","author":"LA Kahale","year":"2018","unstructured":"Kahale LA, Hakoum MB, Tsolakian IG, Alturki F, Matar CF, Terrenato I, Sperati F et al (2018) Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev 6(6):CD006650. https:\/\/doi.org\/10.1002\/14651858.cd006650.pub5","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3132_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","volume":"15","author":"C Frere","year":"2022","unstructured":"Frere C, Farge D, Schrag D, Prata PH, Connors JM (2022) Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 15(1):69. https:\/\/doi.org\/10.1186\/s13045-022-01289-1","journal-title":"J Hematol Oncol"},{"issue":"5","key":"3132_CR39","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1365-2516.2006.01304.x","volume":"12","author":"O Salomon","year":"2006","unstructured":"Salomon O, Steinberg DM, Seligshon U (2006) Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 12(5):490\u2013493. https:\/\/doi.org\/10.1111\/j.1365-2516.2006.01304.x","journal-title":"Haemophilia"},{"issue":"4","key":"3132_CR40","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/ncponc0458","volume":"3","author":"G Agnelli","year":"2006","unstructured":"Agnelli G, Verso M (2006) Therapy insight: venous-catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 3(4):214\u2013222. https:\/\/doi.org\/10.1038\/ncponc0458","journal-title":"Nat Clin Pract Oncol"},{"issue":"7","key":"3132_CR41","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1182\/blood-2018-03-837153","volume":"132","author":"H Decousus","year":"2018","unstructured":"Decousus H, Bourmaud A, Fournel P, Bertoletti L, Labruy\u00e8re C, Presles E, Merah A et al (2018) Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP). Blood 132(7):707\u2013716. https:\/\/doi.org\/10.1182\/blood-2018-03-837153","journal-title":"Blood"},{"issue":"1","key":"3132_CR42","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1161\/ATVBAHA.123.319692","volume":"44","author":"MA Pfeffer","year":"2024","unstructured":"Pfeffer MA, Kohs TCL, Vu HH, Jordan KR, Wang JSH, Lorentz CU, Tucker EI et al (2024) Factor XI Inhibition for the prevention of Catheter-Associated thrombosis in patients with Cancer undergoing central line placement: A phase 2 clinical trial. Arterioscler Thromb Vasc Biol 44(1):290\u2013299. https:\/\/doi.org\/10.1161\/ATVBAHA.123.319692","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10075","key":"3132_CR43","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P (2017) Chronic kidney disease. Lancet 389(10075):1238\u20131252. https:\/\/doi.org\/10.1016\/S0140-6736(16)32064-5","journal-title":"Lancet"},{"issue":"8","key":"3132_CR44","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s11239-024-03059-x","volume":"57","author":"J Grafeneder","year":"2024","unstructured":"Grafeneder J, Langer G, Schoergenhofer C, Eskandary F, Jilma B, Khder Y, Kovcevic Miljevic KD (2024) The factor xi\/xia antibody Abelacimab combined with Enoxaparin inhibits filter clotting in Hemodialysis circuits ex vivo. J Thromb Thrombolysis 57(8):1339\u20131348. https:\/\/doi.org\/10.1007\/s11239-024-03059-x","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"3132_CR45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","volume":"7","author":"M Walsh","year":"2022","unstructured":"Walsh M, Bethune C, Smyth A, Tyrwhitt J, Jung SW, Yu RZ, Wang Y et al (2022) Phase 2 study of the factor XI antisense inhibitor IONIS-FXI(rx) in patients with ESRD. Kidney Int Rep 7(2):200\u2013209. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.011","journal-title":"Kidney Int Rep"},{"issue":"22","key":"3132_CR46","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021011725","volume":"138","author":"CU Lorentz","year":"2021","unstructured":"Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, Wallisch M et al (2021) The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood 138(22):2173\u20132184. https:\/\/doi.org\/10.1182\/blood.2021011725","journal-title":"Blood"},{"issue":"1","key":"3132_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","volume":"106","author":"WC Winkelmayer","year":"2024","unstructured":"Winkelmayer WC, Lensing AWA, Thadhani RI, Mahaffey KW, Walsh M, Pap \u00c1F, Willmman S et al (2024) A phase II randomized controlled trial evaluated antithrombotic treatment with Fesomersen in patients with kidney failure on Hemodialysis. Kidney Int 106(1):145\u2013153. https:\/\/doi.org\/10.1016\/j.kint.2024.02.024","journal-title":"Kidney Int"},{"issue":"2","key":"3132_CR48","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","volume":"30","author":"JI Weitz","year":"2024","unstructured":"Weitz JI, Tank\u00f3 LB, Floege J, Fox KAA, Bhatt DL, Thadhani R, Hung J et al (2024) Anticoagulation with Osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial. Nat Med 30(2):435\u2013442. https:\/\/doi.org\/10.1038\/s41591-023-02794-7","journal-title":"Nat Med"},{"key":"3132_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.thromres.2021.06.010","volume":"204","author":"W Knoll","year":"2021","unstructured":"Knoll W, Fergusson N, Ivankovic V, Wang T-F, Caiano L, Auer R, Carrier M (2021) Extended thromboprophylaxis following major abdominal\/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature. Thromb Res 204:114\u2013122. https:\/\/doi.org\/10.1016\/j.thromres.2021.06.010","journal-title":"Thromb Res"},{"issue":"3","key":"3132_CR50","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jvsv.2021.10.001","volume":"10","author":"ZA Matthay","year":"2022","unstructured":"Matthay ZA, Flanagan CP, Sanders K, Smith EJ, Lancaster EM, Gasper WJ, Kornblith LZ et al (2022) Risk factors for venous thromboembolism after vascular surgery and implications for chemoprophylaxis strategies. J Vasc Surg Venous Lymphat Disord 10(3):585\u2013593e2. https:\/\/doi.org\/10.1016\/j.jvsv.2021.10.001","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"3132_CR51","unstructured":"Patel S (2024) Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71. Presented at: European Society of Cardiology Congress 2024"},{"key":"3132_CR52","doi-asserted-by":"publisher","unstructured":"Thompson A, Fleischmann KE, Smilowitz NR, De Las Fuentes L, Mukherjee D, Aggarwal NR, Ahmad FS 2024, AHA\/ACC\/ACS\/ASNC\/HRS\/SCA et al (2024) \/SCCT\/SCMR\/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery. J Am Coll Cardiol 84(19):1869\u20131969. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.013","DOI":"10.1016\/j.jacc.2024.06.013"},{"issue":"5","key":"3132_CR53","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","volume":"162","author":"JD Douketis","year":"2022","unstructured":"Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, Fargo RA et al (2022) Perioperative management of antithrombotic therapy. Chest 162(5):e207\u2013e243. https:\/\/doi.org\/10.1016\/j.chest.2022.07.025","journal-title":"Chest"},{"issue":"10","key":"3132_CR54","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jtha.2024.07.009","volume":"22","author":"JH Levy","year":"2024","unstructured":"Levy JH, Shaw JR, Castellucci LA, Connors JM, Douketis J, Lindhoff-Last E, Rocca B et al (2024) Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 22(10):2889\u20132899. https:\/\/doi.org\/10.1016\/j.jtha.2024.07.009","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3132_CR55","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jth.15579","volume":"20","author":"O Salomon","year":"2022","unstructured":"Salomon O, Gailani D (2022) A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors. J Thromb Haemost 20(1):32\u201338. https:\/\/doi.org\/10.1111\/jth.15579","journal-title":"J Thromb Haemost"},{"issue":"20","key":"3132_CR56","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/eurheartj\/ehad123","volume":"44","author":"N Van Es","year":"2023","unstructured":"Van Es N, De Caterina R, Weitz JI (2023) Reversal agents for current and forthcoming direct oral anticoagulants. Eur Heart J 44(20):1795\u20131806. https:\/\/doi.org\/10.1093\/eurheartj\/ehad123","journal-title":"Eur Heart J"},{"key":"3132_CR57","doi-asserted-by":"publisher","first-page":"e1028609","DOI":"10.1016\/j.rpth.2025.102860","volume":"9","author":"A Godier","year":"2025","unstructured":"Godier A, Lasne D, Martin A, Pernod G, Albaladejo P, De Maistre E, Fontana P et al (2025) Management of bleeding and invasive procedures in patients treated with anti\u2013factor XI(a) anticoagulants: proposals from the French working group on perioperative haemostasis and French society of thrombosis and haemostasis. Res Pract Thromb Haemost 9:e1028609. https:\/\/doi.org\/10.1016\/j.rpth.2025.102860","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"3132_CR58","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1160\/th09-03-0172","volume":"102","author":"T Livnat","year":"2009","unstructured":"Livnat T, Tamarin I, Mor Y, Winckler H, Horowitz Z, Korianski Y, Bar-Zakay B et al (2009) Recombinant activated factor VII and Tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 102(3):487\u2013492. https:\/\/doi.org\/10.1160\/th09-03-0172","journal-title":"Thromb Haemost"},{"issue":"12","key":"3132_CR59","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1055\/s-0039-1696685","volume":"119","author":"O Salomon","year":"2019","unstructured":"Salomon O, Budnik I, Avishai E, Tamarin I, Bashari D, Dardik R, Livnat T (2019) Single low dose of rFVIIa combined with antifibrinolytic agent is a simple and safe treatment for factor XI-Deficient patients undergoing surgery. Thromb Haemost 119(12):1927\u20131932. https:\/\/doi.org\/10.1055\/s-0039-1696685","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"3132_CR60","doi-asserted-by":"publisher","first-page":"e12591","DOI":"10.1002\/rth2.12591","volume":"5","author":"Y Wu","year":"2021","unstructured":"Wu Y, Schneeweis L, Pickney J, Terragni C, Mail S, An Y, Gordon J et al (2021) Discovery and in vitro characterization of an antibody fragment (Fab) which neutralizes milvexian (BMS-986177\/JNJ-70033093). Res Pract Thromb Haemost 5(Suppl 2):e12591. https:\/\/doi.org\/10.1002\/rth2.12591","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03132-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03132-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03132-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:41:36Z","timestamp":1770644496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03132-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3132"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03132-z","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"9 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}